新型短效非去极化肌肉松剂来源于加兰大胺:设计,合成和药理学评估
Robert Frangež1, Julien Rouleau2, Jordi Molgó3
1Institute of Preclinical Sciences, Veterinary Faculty, University of Ljubljana, Gerbičeva 60, Ljubljana, Slovenia.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|February 11, 2026
概括
两个新型的胺衍生物DR-976和化合物15显示出作为快速起作用的非去极化肌肉松剂的潜力. 这些化合物提供快速恢复和心血管安全,与传统药物不同.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 药物发现 药物发现 药物发现
背景情况:
- 兰胺是众所周知的增强尼古丁性乙胆受体 (nAChRs).
- 开发具有快速可逆性的短期作用,非去极化肌肉松剂对于现代麻醉至关重要.
- 修改galantamine支架可以改变其药理特征,从而导致神经肌肉阻塞.
研究的目的:
- 评估新型胺衍生物DR-976和化合物15作为潜在的短期作用,非去极化肌肉松剂.
- 研究这些化合物的神经肌肉阻断效应和安全性.
- 为了比较它们的疗效和恢复特性与d-tubocurarine (dTC).
主要方法:
- 在麻醉大鼠体内研究,以评估剂量依赖的肌肉抽抑制.
- 在实验室研究中,使用分离的小鼠神经-血膜制剂来确定作用机制.
- 评估心血管参数 (血压,心率,心电图) 和血清电解质.
主要成果:
- 无论是DR-976还是化合物15都表明了剂量依赖的神经肌肉阻塞.
- 与dTC (34分钟) 相比,DR-976 (ED50:0.57毫克/公斤) 和化合物15 (ED50:1.25毫克/公斤) 的恢复时间较快 (17分钟和5分钟).
- 在肌肉类型的nAChR (IC50: 1.45μM),类似于dTC (1.57μM),没有显著的心血管或电解质障碍,DR-976作为竞争对手.
结论:
- DR-976和化合物15是有效的短效,非去极化的神经肌肉阻断剂.
- 这些化合物表现出快速的可逆性和出色的心血管安全性.
- 它们的特性表明它们有可能成为下一代肌肉松剂,用于需要快速恢复的手术.
相关概念视频
Centrally Acting Muscle Relaxants: Therapeutic Uses
1.3K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.3K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.2K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.6K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.6K
Relaxation of Skeletal Muscles
6.0K
The period of muscle contraction primarily influences the duration of stimulation at the neuromuscular junction (NMJ), the presence of free calcium ions in the sarcoplasm, and the availability of energy or ATP to support contractions.
When an action potential reaches the axon terminal, it depolarizes the membrane and opens voltage-gated sodium channels. Sodium ions enter the cell, further depolarizing the presynaptic membrane. This depolarization causes voltage-gated calcium channels to open....
When an action potential reaches the axon terminal, it depolarizes the membrane and opens voltage-gated sodium channels. Sodium ions enter the cell, further depolarizing the presynaptic membrane. This depolarization causes voltage-gated calcium channels to open....
6.0K
Classification of Skeletal Muscle Relaxants
3.1K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.1K
Skeletal Muscle Relaxants: Therapeutic Uses
1.0K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.0K


